16 Primary Results From the Randomized Phase II RIGHT Choice Trial of Premenopausal Patients With Aggressive HR+/HER2− Advanced Breast Cancer Treated With Ribociclib + Endocrine Therapy vs Physician’s Choice Combination Chemotherapy

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement40th Annual Miami Breast Cancer Conference® - Abstracts
Volume 37
Issue suppl 4
Pages: 19-20

Background

Chemotherapy (CT) is the standard of care for advanced breast cancer (ABC) with clinically aggressive features that include rapidly progressing or highly symptomatic disease and life-threatening visceral crisis, which requires rapid disease control. Combination CT is associated with a higher overall response rate (ORR) and longer progression-free survival (PFS) than single-agent CT and may be preferred for those who have a critical disease condition and may tolerate potentially toxic treatment. Ribociclib (RIB) + endocrine therapy (ET) demonstrated statistically significant PFS and overall survival (OS) benefits over ET alone in 3 Phase 3 clinical trials (MONALEESA-2, -3, and -7) in patients with hormone receptor−positive, human epidermal growth factor 2 receptor− negative (HR+/HER2−) ABC, including patients with visceral metastases and a high tumor burden. No data have been published on a head-to-head comparison of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor + ET vs combination CT in the patient population with aggressive HR+/HER2− disease. Here we report the prespecified primary analysis of PFS and key secondary end points from the randomized, open-label, multinational, Phase 2 RIGHT Choice trial.

Materials and Methods

The prespecified PFS analysis was planned after disease progression or death in approximately 110 patients. The study had 80% power to detect a hazard ratio (HR) of 0.67 at a 1-sided α level of 10%. Stratified Cox regression was used to estimate the HR for PFS, time to treatment failure (TTF), and time to response (TTR). TTF was defined as the time from randomization to progression, death, change to other anticancer therapy, or discontinuation. TTR was defined as the time from the date of randomization to the first documentation of either complete response (CR) or partial response (PR) without confirmation (confirmation imaging was not required according to study protocol). The efficacy analyses were performed in all randomized patients, while the safety analysis was performed in all patients who received ≥1 treatment dose. Ten patients randomized to the combination CT arm were not included in the safety set as they did not receive any study treatment; 9 of these patients withdrew consent following knowledge of randomization to the CT arm, and 1 was withdrawn based on the physician’s decision. OS data were immature at the data cutoff (April 12, 2022).

Results

222 pts (112 RIB+ET; 110 CT) were randomized, including pts with symptomatic visceral mets (n=150; 67.6%), rapid disease progression (n = 41; 18.5%), and markedly symptomatic non-visceral mets (n = 31; 14.0%). 116 pts (52.3%) had visceral crises based on guidelines and PI’s judgment. A majority (n = 190; 85.6%) had tumors that were ≥50% ER+. Median follow-up was 24.1 mo; 45.5% and 23.6% of pts remained on treatment in the RIB+ET and combo CT arms. The primary end point was met, with a statistically significant PFS benefit of ≈ 1 year for RIB+ET vs combo CT (mPFS, 24.0 vs 12.3 mo; hazard ratio [HR], 0.54; 95% CI, 0.36-0.79; P = .0007). OS data were immature at data cutoff. mTTF was ≈ 10 mo longer for RIB+ET vs CT (18.6 vs 8.5 mo; HR, 0.45; 95% CI, 0.32-0.63). ORR was similar for RIB+ET vs CT (65.2% vs 60.0%, respectively). No new safety signals were observed in pts on RIB. Lower rates of serious treatment-related adverse events (TRAEs; 1.8% vs 8.0%) and discontinuations of any component of study treatment due to TRAEs (7.1% vs 23.0%) were seen with RIB+ET vs CT, respectively. AEs observed with combination CT were consistent with the published data.

Conclusions

RIGHT Choice is the first prospective study comparing a CDK4/6 inhibitor + ET with combination CT and demonstrating the PFS superiority of RIB+ET over combination CT in patients with HR+/HER2− ABC with aggressive clinical features of rapidly progressing or highly symptomatic disease, including life-threatening visceral crisis

First-line RIB+ET demonstrated a statistically significant PFS benefit (≈ 1 year longer) vs combination CT (24.0 vs 12.3 months; HR, 0.54) in pre-/perimenopausal patients with aggressive HR+/HER2− ABC.

RIB+ET also showed longer TTF than combination CT with similar TTR and ORR between the 2 treatment groups, matching the high tumor response rate seen with combination CT. No new safety signals were observed with RIB+ET

Compared with RIB + ET, combination CT was associated with higher rates of treatment-related AEs, many of which impact QOL.

First-line RIB+ET offers an efficacious, clinically meaningful treatment option for patients with aggressive HR+/HER2− ABC, obviating the need for combination CT and its related toxicities.

AFFILIATIONS:

Melissa Gao,1 Yen-Shen Lu,2 Eznal Izwadi Bin Mohd Mahidin,3 Hamdy Azim,4 Yesim Eralp,5 Yoon-Sim Yap,6 Seock-Ah Im,7 Julie Rihani,8 James Bowles,1 Teresa Delgar Alfaro,1 Jiwen Wu,9 Khemaies Slimane,1 Nagi El Saghir10

1Novartis Pharma AG, Basel, Switzerland.

2National Taiwan University Hospital, Taipei, Taiwan.

3Hospital Kuala Lumpur, Kuala Lumpur, Malaysia.

4School of Medicine, Cairo University, Cairo, Egypt.

5Acibadem Research Institute of Senology, Acibadem University, Istanbul, Turkey.

6National Cancer Centre Singapore, Singapore.

7Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.

8Patient advocate.

9Novartis Pharmaceuticals Corporation, East Hanover, NJ.

10American University of Beirut Medical Center, Beirut, Lebanon.

Articles in this issue

1 Elacestrant Versus Fulvestrant or Aromatase Inhibitor in a Phase 3 Trial Evaluating Elacestrant, an Oral Selective Estrogen Receptor Degrader Versus Standard-of- Care Endocrine Monotherapy for ER+/HER2– Advanced/Metastatic Breast Cancer
1 Elacestrant Versus Fulvestrant or Aromatase Inhibitor in a Phase 3 Trial Evaluating Elacestrant, an Oral Selective Estrogen Receptor Degrader Versus Standard-of- Care Endocrine Monotherapy for ER+/HER2– Advanced/Metastatic Breast Cancer
2 Molecular Characterization of HER2-Low Patients Identifies Basal-Enriched Subset With Poor Clinical Outcomes in Real-world Data
2 Molecular Characterization of HER2-Low Patients Identifies Basal-Enriched Subset With Poor Clinical Outcomes in Real-world Data
3 Real-world Outcomes of Sacituzumab Govitecan in Metastatic Breast Cancer Patients: A Single Institution Experience
3 Real-world Outcomes of Sacituzumab Govitecan in Metastatic Breast Cancer Patients: A Single Institution Experience
4 Datopotamab Deruxtecan (Dato-DXd) + Durvalumab (D) as First-Line (1L) Treatment for Unresectable Locally Advanced/ Metastatic Triple-Negative Breast Cancer (a/mTNBC): Updated Results From BEGONIA, a Phase 1b/2 Study
4 Datopotamab Deruxtecan (Dato-DXd) + Durvalumab (D) as First-Line (1L) Treatment for Unresectable Locally Advanced/ Metastatic Triple-Negative Breast Cancer (a/mTNBC): Updated Results From BEGONIA, a Phase 1b/2 Study
5 Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib Combinations as First- Line Treatment for Advanced or Metastatic Breast Cancer in Realworld Settings in Argentina and Colombia: Results from the IRIS Study
5 Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib Combinations as First- Line Treatment for Advanced or Metastatic Breast Cancer in Realworld Settings in Argentina and Colombia: Results from the IRIS Study
7 EMERALD Phase 3 Trial of Elacestrant Versus Standard-of- Care Endocrine Therapy in Patients With ER+/HER2– Metastatic Breast Cancer: Updated Results by Duration of Prior CDK4/6i in Metastatic Setting
7 EMERALD Phase 3 Trial of Elacestrant Versus Standard-of- Care Endocrine Therapy in Patients With ER+/HER2– Metastatic Breast Cancer: Updated Results by Duration of Prior CDK4/6i in Metastatic Setting
8 Datopotamab Deruxtecan (Dato-DXd) in Advanced Triple- Negative Breast Cancer (TNBC): Updated Results From the Phase 1 TROPION-PanTumor01 Study
8 Datopotamab Deruxtecan (Dato-DXd) in Advanced Triple- Negative Breast Cancer (TNBC): Updated Results From the Phase 1 TROPION-PanTumor01 Study
9 Phase 1 TROPION-PanTumor01 Study Evaluating Datopotamab Deruxtecan (Dato-DXd) in Unresectable or Metastatic Hormone Receptor–Positive/ Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer
9 Phase 1 TROPION-PanTumor01 Study Evaluating Datopotamab Deruxtecan (Dato-DXd) in Unresectable or Metastatic Hormone Receptor–Positive/ Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer
11 Real-world Treatment Patterns and Effectiveness of Palbociclib Plus an Aromatase Inhibitor in Patients With Metastatic Breast Cancer Aged 75 Years or Above
11 Real-world Treatment Patterns and Effectiveness of Palbociclib Plus an Aromatase Inhibitor in Patients With Metastatic Breast Cancer Aged 75 Years or Above
12 TIP HARMONIA SOLTI-2101/ AFT-58: A Head-to-Head Phase III Study Comparing Ribociclib (RIB) and Palbociclib (PAL) in Patients (pts) With Hormone Receptor– Positive/HER2-Negative/HER2- Enriched (HR+/HER2−/HER2-E) Advanced Breast Cancer (ABC)
12 TIP HARMONIA SOLTI-2101/ AFT-58: A Head-to-Head Phase III Study Comparing Ribociclib (RIB) and Palbociclib (PAL) in Patients (pts) With Hormone Receptor– Positive/HER2-Negative/HER2- Enriched (HR+/HER2−/HER2-E) Advanced Breast Cancer (ABC)
13 Improved Sensitivity in Identification of ER- and HER2- Expressing Metastatic Breast Cancers With a Combination of Cell & Cell-Free Liquid Biopsy Analysis
13 Improved Sensitivity in Identification of ER- and HER2- Expressing Metastatic Breast Cancers With a Combination of Cell & Cell-Free Liquid Biopsy Analysis
15 Updated Expert Consensus Recommendations for Managing Hyperglycemia and Rash in Patients With PIK3CA-Mutated, Hormone Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2–Negative (HER2–) Advanced Breast Cancer Treated With Alpelisib
15 Updated Expert Consensus Recommendations for Managing Hyperglycemia and Rash in Patients With PIK3CA-Mutated, Hormone Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2–Negative (HER2–) Advanced Breast Cancer Treated With Alpelisib
16 Primary Results From the Randomized Phase II RIGHT Choice Trial of Premenopausal Patients With Aggressive HR+/HER2− Advanced Breast Cancer Treated With Ribociclib + Endocrine Therapy vs Physician’s Choice Combination Chemotherapy
16 Primary Results From the Randomized Phase II RIGHT Choice Trial of Premenopausal Patients With Aggressive HR+/HER2− Advanced Breast Cancer Treated With Ribociclib + Endocrine Therapy vs Physician’s Choice Combination Chemotherapy
17 A Clinical Systematic Literature Review of Treatments Among Patients With Advanced/ Metastatic HER2+ Breast Cancer
17 A Clinical Systematic Literature Review of Treatments Among Patients With Advanced/ Metastatic HER2+ Breast Cancer
20 TIP ELONA: An Open-Label, Phase 1b-2 Study of Elacestrant, in Combination With Onapristone in Patients With Estrogen Receptor– Positive, Progesterone Receptor– Positive, HER2-Negative Advanced or Metastatic Breast Cancer
20 TIP ELONA: An Open-Label, Phase 1b-2 Study of Elacestrant, in Combination With Onapristone in Patients With Estrogen Receptor– Positive, Progesterone Receptor– Positive, HER2-Negative Advanced or Metastatic Breast Cancer
Related Content